% | $
Quotes you view appear here for quick access.

Horizon Pharma plc Message Board

  • marcpw marcpw Nov 19, 2013 6:42 AM Flag

    convertable bond offering to acquire Vimovo as new product

    1.Vimovo competes with Duexis but it's once a day I believe and comes in 2 different doses so a lot more flexibility and once a day a big advantage.

    2.Also takes on patent litigation which I believe is about generics for Vimovo

    3. MConverts often drive stock price down because arbs but the converts and short the common to hedge.

    4. HZNP also structuring deal to limit kilution. PR and 8Ks are out there now.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • very smart move by the company - HZNP also provided guidance for non-gaap profitability, means Vimovo will be accreditive to earnings almost right from the beginning with projected FY14 US sales of around $50 mln.

      Company got rid of the old debt, acquired accreditive US rights for a new drug and projected profitability and no further dilution going forward. That's what I call great.

      Stock should move up big time going forward. Investors should buy any dips.

    • This transaction much bigger. It raises 1$50M and they use $70M to will pay off all the old debt.
      19M for call option transaction to make the transaction less dilutive and I'm not sure but maybe it will mitigate the buyers from shorting the common on a hedge. AZN will keep responsibility until transferred to HZNP.

      Since it's complicated hard to say for sure how stock would react. My guess is it could go down initially but if great value is seen in selling Vimovo then it could even pop. Also I think it's a positive they're getting rid of that miserable current debt with its covenants.

21.81+0.13(+0.60%)Nov 25 4:00 PMEST